Raymond Wadlow, MD

VCS Physicians

Raymond Wadlow, MD Headshot

During a time of immense stress, cancer patients are faced with an increasingly complex array of therapeutic options. As their oncologist, I strive to empower and guide them to a firm understanding of their disease and potential treatments. By establishing a partnership with patients and their loved ones, I find that patients are better able to utilize the wealth of resources available to them as they continue to pursue high quality, meaningful lives.

Work and Credentials:

Primary Location

Fairfax Office

Position

Medical Oncologist

Board Certification

Medical Oncology and Internal Medicine

Fellowship

Dana-Farber/Partners Cancer Care, Medical Oncology

Internship

Hospital of the University of Pennsylvania

Residency

Hospital of the University of Pennsylvania

Medical School

University of Virginia

College

Dartmouth College

Dr. Wadlow completed his internship and residency at the Hospital of the University of Pennsylvania. Dr. Wadlow then went on to complete his fellowship at Dana-Farber/Partners Cancer Care, holding academic appointments as a clinical fellow as well as an instructor. He is board certified in medical oncology and internal medicine.

As Co-director of the Virginia Cancer Specialists (VCS) Research Institute, Dr. Wadlow helps run clinical trials that study novel and targeted therapies for cancer. Dr. Wadlow has special interest and expertise in gastrointestinal malignancies and breast cancer. Dr. Wadlow is also a member of the American Society of Clinical Oncology.

In his spare time, Dr. Wadlow enjoys relaxing with his family, reading novels, skiing, hiking, and traveling as much as possible.


 

 

 

 

Practice Blog

February 1, 2017

Molecular Testing and Precision Medicine for Patients with Gastrointestinal Cancers; R. Wadlow M.D.

Read More

Physician Publications

May 11, 2017

Molecular Testing to Optimize and Personalize Decision Making in the Management of Colorectal Cancer

Read More
February 1, 2015

A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma

Read More
July 15, 2014

A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma

Read More

More Publications by Raymond Wadlow, MD

February 5, 2014

Mutational analysis and clinical correlation of metastatic colorectal cancer.

Read More
June 3, 2013

A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.

Read More
June 2, 2013

A phase II clinical trial of ganetespib (STA-9090) in previously treated patients with advanced esophagogastric cancers.

Read More
June 15, 2012

Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer

Read More
March 11, 2012

Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy

Read More
December 30, 2011

Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab.

Read More
August 1, 2010

The role of targeted agents in preoperative chemoradiation for rectal cancer

Read More
November 5, 2009

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

Read More
May 26, 2005

Genome-wide views of cancer metastasis

Read More

Clinical Trials (7)

Clinical Trial 8951-CL-0103

A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors have High or Intermediate Claudin (CLDN) 18.2 Expression


Clinical Trial 101-18101

An Open-label Phase 1b Study of ORIC-101 in Combination with Anticancer Therapy in Patients with Advanced or Metastatic Solid Tumors


Clinical Trial 18109

A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of FN (20170758)


Clinical Trial 18233

A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Gastrointestinal Malignancies


Clinical Trial 18-162

An open-label, multi-center, phase 1b/2 study to evaluate the safety and efficacy of copanlisib in combination with nivolumab in patients with advanced solid tumors (19769)


Clinical Trial D6070C00005

A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab(MEDI9447) with or without Durvalumab in Combination with Chemotherapy in Subjects with Metastatic Pancreatic Ductal Adenocarcinoma

All Clinical Trials for Raymond Wadlow, MD

Clinical Trial 8951-CL-0103

A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors have High or Intermediate Claudin (CLDN) 18.2 Expression

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03505320

ClinicalTrials.gov Link:

Click Here


Clinical Trial 101-18101

An Open-label Phase 1b Study of ORIC-101 in Combination with Anticancer Therapy in Patients with Advanced or Metastatic Solid Tumors

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03928314

ClinicalTrials.gov Link:

Click Here


Clinical Trial 18109

A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of FN (20170758)


Clinical Trial 18233

A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Gastrointestinal Malignancies

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03720678

ClinicalTrials.gov Link:

Click Here


Clinical Trial 18-162

An open-label, multi-center, phase 1b/2 study to evaluate the safety and efficacy of copanlisib in combination with nivolumab in patients with advanced solid tumors (19769)

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03735628

ClinicalTrials.gov Link:

Click Here


Clinical Trial D6070C00005

A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab(MEDI9447) with or without Durvalumab in Combination with Chemotherapy in Subjects with Metastatic Pancreatic Ductal Adenocarcinoma

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03611556

ClinicalTrials.gov Link:

Click Here


Clinical Trial 8951-CL0103

A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors have High or Intermediate Claudin (CLDN) 18.2 Expression

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03505320

ClinicalTrials.gov Link:

Click Here

Primary Location

Fairfax Office Office

Fairfax Office

Learn More

Other Locations

Awards

January 1, 2019

Northern Virginia Magazine Top Doctor 2019


January 1, 2018

2018 Washingtonian Magazine Top Doctor Nomination


January 1, 2018
Northern Virginia Magazine Top Doctors 2018

Northern Virginia Magazine Top Doctors 2018


November 1, 2017
Washingtonian Magazne Top Doctors 2017

Washingtonian Magazne Top Doctors 2017


September 9, 2016
Washingtonian Magazine

Washingtonian Top Doctor 2016